Cowden Syndrome Market Research Report - Forecast till 2027

Cowden Syndrome Market Research Report: By Site (Breast, Thyroid, Colorectal, Kidney, Skin), Treatment (Genetic Testing, Chemotherapy, Targeted Therapy, Surgery & Radiation Therapy, Hormone Therapy), End User (Hospital & Clinics) - Forecast till 2027

ID: MRFR/MED/3660-HCR | | Region: Global | 85 Pages         

Cowden Syndrome Market Scenario:


Cowden syndrome is an inherited condition, which is characterized by multiple, noncancerous growths on various parts of the body. People with the syndrome usually have a large head, benign tumors of the hair follicle, and white papules with a smooth surface in the mouth. The major cause of the syndrome is still unknown, however, genetic factors are considered as a major factor for the cowden syndrome market growth. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in the coming future. According to a study, it is observed that in 99% of the patients suffering from this syndrome shows various symptoms such as breast carcinoma, colorectal polyposis, conjunctival hamartoma, generalized hyperkeratosis, goiter, and others. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The cowden syndrome market is majorly driven by the increasing prevalence of Cowden syndrome across the globe. Due to lack of treatment, governments of various countries have started supporting the manufacturers for research and development. Additionally, increasing government support for research & development, rising healthcare expenditure, and changing lifestyle have fuelled the cowden syndrome market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment and the high cost of the medicines may slow the growth of the cowden syndrome market during the forecasted period.


The cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories


 


Figure 1- Market Synopsis of Cowden Syndrome Market Research, by Treatment 2016 (%) Cowden Syndrome Market


Sources: WHO, cancer research UK, American Cancer Society


Segmentation


The Cowden syndrome market is segmented on the basis of site, treatment and end users.


On the basis of the site, the cowden syndrome market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.


On the basis of the treatment, the cowden syndrome market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.


On the basis of end users, the cowden syndrome market is segmented into hospital & clinics, ambulatory care centers, and others.


Regional Analysis


The Americas dominate the Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.


Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.


On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.


Market Assessment


Cowden Syndrome Market 2017


Sources- WHO, cancer research UK, American Cancer Society


Key Players in Cowden Syndrome Market


Some of key the players in the cowden syndrome market are Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)



Report Scope:

Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.7% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Site, Treatment and End users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of Cowden syndrome across the globe
  • Increasing government support for research & development
  • Rising healthcare expenditure
  • Changing lifestyle


  • Speak to Analyst Ask for Customization